Alzheimer's disease (AD) and frontotemporal dementia (FTD) were long viewed as distinct entities — amyloid-beta and tau-driven neurodegeneration versus frontotemporal lobar degeneration (FTLD) characterized by tau or TDP-43 pathology. However, research over the past decade has revealed extensive molecular overlap: TDP-43 proteinopathy is present in approximately 40-57% of AD cases at autopsy, while tau pathology appears in many FTD subtypes, creating a complex landscape of co-pathology that blurs traditional diagnostic boundaries[@neumann2006][@josephsmatter2011].
This page systematically compares the molecular mechanisms of tau and TDP-43 involvement across AD and FTD, examines their distinct and shared spreading mechanisms, delineates clinical phenotypes arising from co-pathology, and explores therapeutic implications of this overlap.
TDP-43 pathology in AD was first formally described as "TDP-43 type A" inclusions in 2006 by Arai et al., who observed that a subset of AD cases harbored TDP-43-positive, tau-negative inclusions in the medial temporal lobe[@arai2006]. Subsequent studies by Neumann et al. and others established that TDP-43 inclusions in AD follow a stereotypical pattern: beginning in the hippocampal formation, spreading to the amygdala, and eventually reaching the neocortex in advanced cases[@neumann2006].
Alzheimer's disease (AD) and frontotemporal dementia (FTD) were long viewed as distinct entities — amyloid-beta and tau-driven neurodegeneration versus frontotemporal lobar degeneration (FTLD) characterized by tau or TDP-43 pathology. However, research over the past decade has revealed extensive molecular overlap: TDP-43 proteinopathy is present in approximately 40-57% of AD cases at autopsy, while tau pathology appears in many FTD subtypes, creating a complex landscape of co-pathology that blurs traditional diagnostic boundaries[@neumann2006][@josephsmatter2011].
This page systematically compares the molecular mechanisms of tau and TDP-43 involvement across AD and FTD, examines their distinct and shared spreading mechanisms, delineates clinical phenotypes arising from co-pathology, and explores therapeutic implications of this overlap.
TDP-43 pathology in AD was first formally described as "TDP-43 type A" inclusions in 2006 by Arai et al., who observed that a subset of AD cases harbored TDP-43-positive, tau-negative inclusions in the medial temporal lobe[@arai2006]. Subsequent studies by Neumann et al. and others established that TDP-43 inclusions in AD follow a stereotypical pattern: beginning in the hippocampal formation, spreading to the amygdala, and eventually reaching the neocortex in advanced cases[@neumann2006].
The prevalence of TDP-43 pathology in AD varies by cohort and detection method:
Tau pathology in FTD is heterogeneous, spanning multiple 3R, 4R, and mixed 3R/4R tauopathies. The FTLD-tau spectrum includes:
PART represents a key intersection between AD and FTD. Josephs et al. (2014) described PART as a distinct entity characterized by:
The [APOE](/genes/apoe) gene strongly influences tau-TDP-43 co-pathology patterns in AD:
| Feature | Alzheimer's Disease | Frontotemporal Dementia |
|---------|--------------------|------------------------|
| Primary tau species | 3R+4R mixed | 3R (Pick's), 4R (PSP, CBD), or mixed |
| Neurofibrillary tangle distribution | Braak stages I-VI (limbic → isocortex) | Regional: frontal/temporal cortex; variable brainstem |
| Topographic pattern | Hippocampus → entorhinal → neocortex | Frontal, temporal poles, basal ganglia |
| Amyloid-beta co-pathology | Universal (>95%) | Rare (<5% in pure FTLD-tau) |
| Spreading mechanism | Prion-like templating, exosome-mediated | Prion-like, exosome, trans-synaptic |
| Tau isoform expression | Balanced 3R/4R | Disease-specific imbalance |
| Post-translational modifications | Hyperphosphorylation, truncation, glycation | Hyperphosphorylation, specific conformational changes |
| Feature | AD-Associated TDP-43 | FTD (FTLD-TDP) |
|---------|----------------------|----------------|
| Frequency in disease | 20-57% of AD cases | ~50% of FTD cases |
| Inclusion morphology | Dense, compact cytoplasmic inclusions; dystrophic neurites | Type A (compact), Type B (lentiform), Type C (neuronal intranuclear) |
| Anatomical distribution | Hippocampus → amygdala → neocortex | Frontal cortex, basal ganglia, motor neurons |
| C9orf72 association | Rare | Common (40% of familial FTD) |
| Dipeptide repeat proteins | Absent | Present in C9orf72 cases |
| Primary vs secondary | Secondary to AD neuropathology | Primary driver of neurodegeneration |
| Relationship to tau | Co-existing, often accelerates cognitive decline | May co-exist, especially in FTD with motor neuron disease |
LATE-NC was formalized as a distinct neuropathological change in 2019, representing:
Tau propagation in both AD and FTD follows prion-like principles[@carraro2024]:
Template-driven misfolding: Pathological tau recruits native tau molecules, converting them into the same conformer. This creates "tau strains" that are disease-specific and maintain their identity during propagation[@kaufman2016][@sanders2014].
Cell-to-cell spread: Multiple mechanisms facilitate intercellular tau transfer:
TDP-43 spreading differs mechanistically from tau in several key ways[@polanco2023]:
Phase separation and granule formation: Under cellular stress, TDP-43 undergoes liquid-liquid phase separation (LLPS), forming stress granules and other membrane-less organelles. This is a physiological response to stress, but in disease states:
Evidence for direct cross-seeding is limited but emerging:
Patients with AD can present with FTD-like clinical phenotypes due to:
Conversely, FTD patients may present with AD-like syndromes:
Logopenic variant PPA (lvPPA):
The overlap between AD and FTD creates both challenges and opportunities for therapy development[@serra2020]:
Anti-tau therapies (potentially relevant for both AD and FTD-tau):
Both tau and TDP-43 aggregation respond to shared upstream stressors, suggesting common therapeutic targets:
| Upstream Target | Mechanism | Therapeutic Approach |
|----------------|-----------|---------------------|
| Autophagy impairment | Reduced clearance of protein aggregates | mTOR inhibitors, trehalose, BET inhibitors |
| Neuroinflammation | Microglial activation promotes spreading | TREM2 agonists, anti-inflammatory approaches |
| Oxidative stress | Accelerates aggregation kinetics | Nrf2 activators, antioxidants |
| Mitochondrial dysfunction | Energy stress promotes stress granules | Mitochondrial biogenesis activators |
| RNA dysregulation | TDP-43 loss of function disrupts splicing | Splicing modulators |
| Nuclear pore dysfunction | Impaired nuclear-cytoplasmic transport | Nuclear transport modulators |
For trials targeting AD-FTD overlap syndromes:
| Dimension | Alzheimer's Disease | Frontotemporal Dementia |
|-----------|--------------------|------------------------|
| Primary proteinopathy | Amyloid-beta + tau | Tau (FTLD-tau) or TDP-43 (FTLD-TDP) |
| TDP-43 co-pathology rate | 20-57% | 50% (FTLD-TDP subtype) |
| Tau isoform balance | 3R+4R mixed | 3R, 4R, or mixed (disease-dependent) |
| Spreading mechanism | Prion-like templating | Prion-like (tau) or phase separation (TDP-43) |
| Primary anatomical target | Hippocampus, entorhinal cortex | Frontal, temporal cortex; basal ganglia |
| Amyloid co-pathology | Universal | Rare in pure FTD |
| Genetic drivers | APOE4, TREM2, ABCA7 | MAPT, GRN, C9orf72, VCP, TMEM106B |
| Key clinical phenotypes | Memory, visuospatial, language | Behavioral, language, motor |
| Therapeutic targets | Anti-Aβ, anti-tau, anti-TDP-43 | Anti-tau, anti-TDP-43, gene-specific |
| Biomarkers | CSF Aβ42, p-tau217, tau PET | CSF NfL, genetic testing, tau PET (limited) |
The overlap between AD and FTD at the molecular level reveals that these traditionally separated diseases share more than previously appreciated. TDP-43 pathology is present in a substantial minority of AD cases and accelerates cognitive decline, while tau pathology is a feature of many FTD subtypes. The emergence of PART and LATE-NC as distinct entities further emphasizes that the neuropathological landscape of late-life dementia is a continuum rather than discrete categories.
Understanding the mechanistic intersection of tau and TDP-43 across AD and FTD has several practical implications:
The dense cross-linking between tau and TDP-43 biology across AD and FTD makes a compelling case for integrated therapeutic strategies that address both proteinopathies, particularly in the aging population where co-pathology is the norm rather than the exception.